GlaxoSmithKline (GSK – Research Report ... being broadly in line with consensus but showing signs of weakness in the vaccine segment. This is attributed to disappointing performances from ...
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
Pharmaceutical giant GlaxoSmithKline will buy the oncology biotech company ... Endpoints News notes that Zejula is one of several PARP inhibitors that have reached the market, after AstraZeneca gained ...
United States, New York, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Introspective Market Research reports that the Analgesics Market around the world was USD 87.59 billion in 2023 and it was projected to ...
BURLINGAME, CA, UNITED STATES, January 9, 2025 /EINPresswire / -- This report on the Diabetic Neuropathy Market offers an comprehensive analysis of the current trends, Market size, and projections ...
London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback